Key Stats for AstraZeneca Stock
- Price change for AstraZeneca stock: -7%
- $AZN Stock Price as of Aug. 3: $158
- 52-Week High: $213
- $AZN Stock Price Target: $214
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
AstraZeneca (AZN) stock dropped as much as 7% on Monday after the Financial Times reported the company had been in talks about a potential merger with U.S. rival Bristol Myers Squibb. If the deal happens, it could value the combined company at around $400 billion, making it one of the biggest pharmaceutical mergers ever.
Neither company confirmed the report. AstraZeneca declined to comment, and Bristol Myers didn’t respond right away.
Sources told the FT a deal may never actually happen, but the news alone was enough to send AstraZeneca stock sharply lower, while Bristol Myers shares jumped 6% in U.S. premarket trading.
The timing caught a lot of people off guard.
- AstraZeneca just posted strong Q2 results last week, with cancer treatments driving about $25 billion in 2025 sales, nearly half the company’s total revenue.
- Cardiovascular, renal and metabolism drugs added another $12 billion.
- Under CEO Pascal Soriot, who’s led the company for 14 years, AstraZeneca’s share price has more than quadrupled and outpaced both the FTSE 100 and its British rival GSK.
- Bristol Myers, on the other hand, is dealing with a tougher road ahead.
- Its market cap sits around $133 billion, and it’s facing loss of patent protection on major drugs like blood thinner Eliquis and cancer treatment Opdivo starting next year.
- That’s expected to weigh on Bristol Myers’ growth going forward.
Analysts openly questioned the logic. Jefferies said it was “a bit perplexed” by the news, noting that AstraZeneca doesn’t need financial engineering given how strong its growth story already is.
Citi called it a “surprise” given AstraZeneca’s pipeline is considered best-in-class in the industry.
One possible reason for the talks could be AstraZeneca’s push into the U.S. market. The company completed a direct listing on the New York Stock Exchange earlier this year.
U.S. sales already made up 42% of AstraZeneca’s total revenue in the first half of 2026, and Bristol Myers gets an even higher share, 69%, of its revenue from the U.S.
The combined company would create a major oncology powerhouse, though the two businesses focus on different areas.
AstraZeneca is stronger in solid tumors, while Bristol Myers leans more into blood cancers and cell therapies. That overlap in oncology, cardiovascular disease, and immunology could also draw scrutiny from antitrust regulators.
See analysts’ growth forecasts and price targets for AstraZeneca stock (It’s free) >>>
What the Market Is Telling Us About AstraZeneca Stock
The sharp drop in AstraZeneca stock shows investors are uneasy about the idea, not excited by it.
This isn’t a case of the market cheering a growth opportunity. It’s a case of investors questioning why a company performing this well would need to merge with one facing patent cliffs and slowing growth.
It’s also worth noting this isn’t the first tough news cycle for AstraZeneca lately.
Earlier this month, a late-stage heart disease drug trial failed to meet its target, which already raised some questions about management’s messaging.
Even so, most analysts still think the company’s $80 billion sales target for 2030 remains achievable, deal or no deal.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does AstraZeneca Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
